# A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

> **NCT06858813** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 232 (estimated)

## Conditions studied

- Hepatocellular Cancer
- Squamous-Cell Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** ABBV-324

## Key facts

- **NCT ID:** NCT06858813
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-14
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858813, "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06858813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*